Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference
Rhea-AI Summary
Cocrystal Pharma (Nasdaq: COCP) will present at Noble Capital Markets’ 21st Emerging Growth Equity Conference on Wednesday, December 3, 2025 at 10:00 AM ET. James Martin, CFO and co-CEO, will give a company overview and a clinical progress update at the Executive Education Complex of Florida Atlantic University in Boca Raton, Florida.
A video webcast of the presentation will be posted on December 4, 2025 on the company website and will be archived for 90 days. Interested investors can attend the conference at a discounted rate using code COCPNOBLECON.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, COCP declined 2.83%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Key biotech peers such as IMNN (-2.59%), BIVI (-2.58%), CYCC (-5.84%) and PRTG (-10.39%) showed declines, while momentum scans flagged CLRB up 4.23% without news, suggesting mixed sector action rather than a unified move tied to this conference update.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | Conference presentation | Neutral | -2.8% | Announcement of NobleCon 21 company overview and clinical progress presentation. |
| Nov 14 | Earnings and pipeline | Neutral | +0.0% | Q3 2025 results with IND clearance, NIH award and recent financings. |
| Oct 30 | Insider placement | Positive | +1.9% | Insider-led private placement with units and warrants for clinical funding. |
| Oct 27 | NIH SBIR award | Positive | +4.2% | Non-dilutive NIH/NIAID SBIR Phase I funding for influenza program. |
| Oct 02 | Conference presentation | Neutral | -3.2% | Noble Capital virtual equity conference presentation with Q&A and meetings. |
Recent conference-related announcements for Cocrystal have coincided with modest share price declines, while funding and non-dilutive award news tended to see flat to positive reactions.
Over the past few months, Cocrystal reported several notable events. On Oct 27, 2025 it received a $500,000 NIH SBIR Phase I award, which saw a positive price reaction. A private placement with insiders on Oct 30, 2025 also drew a favorable move. In contrast, Noble Capital Markets conference announcements on Oct 9, 2025 and Dec 3, 2025 were followed by modest pullbacks. Earnings and pipeline updates on Nov 14, 2025 produced little immediate share response.
Market Pulse Summary
This announcement highlights Cocrystal’s upcoming NobleCon 21 presentation on December 3, 2025, where management plans to give a company overview and clinical progress update, followed by a webcast archived for 90 days. Historically, similar conference appearances have not been major trading catalysts, while financings and non‑dilutive awards had clearer impact. Investors may focus on any new clinical details or strategic disclosures that go beyond prior updates.
AI-generated analysis. Not financial advice.
BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a Company overview and clinical progress update at NobleCon 21 – Noble Capital Markets 21st Emerging Growth Equity Conference on Wednesday, December 3, 2025 at 10:00 am Eastern time. The conference is being held at the Executive Education Complex of Florida Atlantic University in Boca Raton, Florida.
Interested investors and guests of Cocrystal Pharma are welcome to attend the conference at a discounted rate. Please register here using the discount code COCPNOBLECON.
A video webcast of the Cocrystal presentation will be available on December 4, one day after the live event, on the Company's website and archived for 90 days.
About Noble Capital Markets, Inc.
Noble Capital Markets is a research-driven investment bank that has supported small and microcap companies since 1984. As a FINRA and SEC licensed broker dealer, Noble provides institutional-quality equity research, merchant and investment banking, and order execution services. In 2018, Noble launched Channelchek—an investor community dedicated exclusively to public small and micro-cap companies and their industries. Channelchek is the first service to offer investors free institutional-quality research without a subscription.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that addresses significant unmet needs by developing innovative antiviral treatments for challenging diseases including influenza, viral gastroenteritis, COVID, and hepatitis. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
Contact:
Alliance Advisors IR
Jody Cain
310-691-7100
jcain@allianceadvisors.com
# # #
FAQ
When will Cocrystal Pharma (COCP) present at NobleCon 21?
Who will deliver Cocrystal Pharma's (COCP) presentation at NobleCon 21?
When and where will the Cocrystal Pharma (COCP) presentation webcast be available?
How can investors attend NobleCon 21 at a discount for Cocrystal Pharma (COCP)?
Where is Noble Capital Markets’ 21st Emerging Growth Equity Conference being held?
